What Is Activated Protein C?

Human activated protein C, English name is CTC-111, alias Anact C, it is a blood system drug.

Human activated protein C

Human activated protein C, English name is CTC-111, alias Anact C, it is a blood system drug.

Chinese name

Human activated protein C

Foreign name

Human activity protein C

Alias

Anact C, CTC-111

Types of

Blood System Drugs

Hematology Drugs> Fibrinolytic Drugs

2500U. In addition, water for injection contains 25 mg of human serum albumin, 5.9 mg of sodium citrate, and 5 mg of glycine per milliliter.

Active protein C (APC) is a double-chain glycoprotein composed of a light chain (molecular weight 25,000) consisting of 155 amino acid residues and a heavy chain consisting of 250 amino acid residues connected by a disulfide chain.

1. Human activated protein C is activated by thrombin to selectively inactivate the activated clotting factors Va and Va, which has an anticoagulant effect.

2. After human activated protein C removes sodium citrate, it can inhibit thrombin production and platelet aggregation. After removing human serum albumin, it can prolong APTT in a concentration-dependent manner.

3. Human activated protein C also has a fibrinolytic promoting effect, which can inhibit plasminogen activator, thereby maintaining the activity of tissue-type plasminogen activator.

Thrombophlebitis (deep venous thrombosis) and acute pulmonary thromboembolism due to congenital protein C (PC) deficiency.

People who are allergic to human activated protein C, pregnant women, and breastfeeding are prohibited.

1. (1) Patients with hemolytic and iron deficiency anemia and immunosuppressed patients should be used with caution. (2) The elderly and infants should be used with caution.

2. Human activated protein C can only be used in patients with PC deficiency. It means: (1) PC activity is below 60%, and its activity ratio or antigen ratio to factor is less than 0.7; (2) PC activity is <60% , And a history of thrombosis; (3) PC activity 60% but <80%, activity ratio or antigen ratio to factor is less than 0.7, plus a history of thrombosis, patients with congenital PC deficiency in the family; (5) ) Where genetic analysis confirms PC deficiency.

3. Congenital activated PC refractory disease (ie, patients with Leiden mutation in factor V), human activated protein C is not effective.

1. May cause allergic reactions.

2. May be infected with B19 virus and hepatitis virus.

1. Human activated protein C is dissolved with the water for injection. Generally, human activated protein C200 300U is added to 500 1000ml of 5% glucose or 0.9% sodium chloride injection slowly within 24 hours. If the symptoms do not improve after 6 days of use, the drug should be considered discontinued. The dose is determined according to age and symptoms.

2. Human activated protein C cannot be mixed with amino acid injections.

Human activated protein C cannot be combined with antioxidants (sodium bisulfite, sodium metabisulfite, etc.), because it can significantly reduce human activated protein C activity.

Human activated protein C is a double-chain glycoprotein composed of a light chain (molecular weight 25 000) consisting of 155 amino acid residues and a heavy chain consisting of 250 amino acid residues connected by a disulfide chain. Human activated protein C is selectively inactivated by activating thrombin after activating thrombin, and has anticoagulant effect. In addition, after human activated protein C removes sodium citrate, it can inhibit thrombin production and platelet aggregation. Human activated protein C also promotes fibrinolysis. It is mainly used to treat deep venous thrombosis and acute pulmonary thromboembolism caused by congenital protein C deficiency.